DOCSLIB.ORG

HA Standard Drug Formulary (Drug List) 050218

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HA Standard Drug Formulary (Drug List) 050218 LC Paper No. CB(2)994/04-05(01) HOSPITAL AUTHORITY STANDARD DRUG FORMULARY (DRAFT PROPOSAL – as of 18 Feb 2005) Notes (1) The drugs may either be listed as generic or proprietary names, where appropriate. (2) Some drugs may appear in more than one category due to different formulations and/or indications. (3) The “Special” drugs will be prescribed as clinically indicated based on the specified indications. (4) Based on operational logistics and needs, individual cluster / hospital may only stock part of the drugs listed in the HA Standard Drug Formulary. Patient will be provided with the appropriate drug (preparation) within a class of drug listed in the HA Standard Drug Formulary. (5) The Specialty Panels and Drug Utilisation Review Committee of the Hospital Authority will review and may revise this draft HA Standard Drug Formulary based on the feedback from relevant parties during the internal and external consultation period. HA Standard Drugs Non-HA Standard Drugs General Drugs Special Drugs With Safety Net Without Safety Net 1 Gastro-intestinal system 1.1 Dyspepsia and gastro-oesophageal reflux disease ALUMAG (OR EQUIV) ALUMINIUM HYDROXIDE CHARCOAL ACTIVATED DIMETHYLPOLYSILOXANE GASTROCAINE (OR EQUIV) GAVISCON (OR EQUIV) GELUSIL (OR EQUIV) LANTACID (OR EQUIV) MAGNESIUM TRISILICATE MUCAINE (OR EQUIV) MYLANTA (OR EQUIV) SIMEGEL (OR EQUIV) SIMETHICONE TRIACT (OR EQUIV) 1.2 Antispasmodics and other drugs altering gut motility ALVERINE CITRATE CISAPRIDE ATROPINE SULPHATE BELLADONNA DONNATAL (OR EQUIV) HYOSCINE MEBEVERINE HCL OTILONIUM BROMIDE OXYPHENCYCLIMINE HCL PEPPERMINT OIL PROPANTHELINE BROMIDE TRIMEBUTINE MALEATE 1.3 Ulcer-healing drugs FAMOTIDINE CIMETIDINE RANITIDINE (IV) RANITIDINE (ORAL) BISMUTH SUBCITRATE RANITIDINE BISMUTH CITRATE SUCRALFATE ESOMEPRAZOLE MISOPROSTOL LANSOPRAZOLE LIBRAX (OR EQUIV) OMEPRAZOLE PANTOPRAZOLE RABEPRAZOLE HA Standard Drugs Non-HA Standard Drugs General Drugs Special Drugs With Safety Net Without Safety Net 1.4 Acute diarrhoea DIOCTAHEDRAL SMECTITE KAOLIN KAOLIN AND PECTIN LOMOTIL (OR EQUIV) LOPERAMIDE HCL 1.5 Chronic bowel disorders ENTOCORT MESALAZINE MESALAZINE (SUPP/ENEMA) OLSALAZINE SODIUM PREDNISOLONE (FOAM/ENEMA) SULPHASALAZINE 1.6 Laxatives AGIOCUR (OR EQUIV) AGIOLAX (OR EQUIV) BISACODYL BISACODYL (SUPP) DOCUSATE SODIUM FLEET (OR EQUIV) (ENEMA) FLEET PHOSPHO-SODA BUFFERED SALINE GLYCERIN (SUPP/ENEMA) LACTULOSE LIQUID PARAFFIN MAGNESIUM CITRATE METAMUCIL (OR EQUIV) MICROLAX (OR EQUIV) (ENEMA) NATURLAX SUGAR-FREE (OR EQUIV) NORMACOL PLUS (OR EQUIV) PEGLYTE (OR EQUIV) PERI-COLACE (OR EQUIV) POLYETHYLENE GLYCOL SENNATOSIDE B SOAP ENEMA STERCULIA 1.7 Local preparations for anal and rectal disorders ANUSOL (OR EQUIV) CINCHOCAINE HCL (TOPICAL) FAKTU (OR EQUIV) GLYCERYL TRINITRATE (TOPICAL) PHENOL ROWATANAL (OR EQUIV) ULTRAPROCT (OR EQUIV) ULTRAPROCT N (OR EQUIV) XYLOPROCT (OR EQUIV) (SUPP) 1.9 Drugs affecting intestinal secretions BILSAN (OR EQUIV) COMBIZYM (OR EQUIV) PANCREATIN PANKREOFLAT (OR EQUIV) URSODEOXYCHOLIC ACID 1.A Miscellaneous (Gastro-intestinal system) ENZYPLEX (OR EQUIV) METHYLCELLULOSE 2 Cardiovascular system 2.1 Positive inotropic drugs DIGOXIN METILDIGOXIN 2.2 Diuretics AMILORIDE HCL BUMETANIDE DYAZIDE (OR EQUIV) FRUSEMIDE HYDROCHLOROTHIAZIDE HA Standard Drugs Non-HA Standard Drugs General Drugs Special Drugs With Safety Net Without Safety Net INDAPAMIDE MANNITOL METHYCLOTHIAZIDE METOLAZONE MODURETIC (OR EQUIV) SPIRONOLACTONE 2.3 Anti-arrhythmic drugs AMIODARONE HCL ATROPINE SULPHATE DISOPYRAMIDE FLECAINIDE ACETATE PROCAINAMIDE HCL PROPAFENONE HCL QUINIDINE 2.4 Beta-adrenoceptor blocking drugs ACEBUTOLOL (HCL) ATENOLOL BISOPROLOL FUMARATE CARVEDILOL CELIPROLOL HCL LABETALOL HCL METOPROLOL NADOLOL PINDOLOL PROPRANOLOL HCL SOTALOL HCL LODOZ (OR EQUIV) TENORETIC (OR EQUIV) 2.5 Drugs affecting the renin-angiotensin system and some other antihypertensive drugs HYDRALAZINE DOXAZOSIN CILAZAPRIL MINOXIDIL TERAZOSIN QUINAPRIL NITROPRUSSIDE DIHYDRATE SODIUM CANDESARTAN CLONIDINE HCL IRBESARTAN METHYLDOPA LOSARTAN RESERPINE TELMISARTAN PHENOXYBENZAMINE HCL VALSARTAN PHENTOLAMINE METHANESULPHONATE PRAZOSIN (HCL) CAPTOPRIL ENALAPRIL MALEATE FOSINOPRIL SODIUM LISINOPRIL PERINDOPRIL TERTBUTYLAMINE RAMIPRIL 2.6 Nitrates, calcium-channel blockers, and potassium-channel activators GLYCERYL TRINITRATE AMLODIPINE ISRADIPINE ISOSORBIDE DINITRATE FELODIPINE NITRENDIPINE ISOSORBIDE MONONITRATE LACIDIPINE DILTIAZEM LERCANIDIPINE NIFEDIPINE NIFEDIPINE ER NIMODIPINE CILOSTAZOL VERAPAMIL HCL NAFTIDROFURYL OXALATE ACTOVEGIN (OR EQUIV) OXPENTIFYLLINE DUXARIL (OR EQUIV) ALPROSTADIL GINKGO BILOBA EXTRACT HYDERGINE (OR EQUIV) INSTENON (OR EQUIV) NICERGOLINE 2.7 Sympathomimetics ADRENALINE DOBUTAMINE DOPAMINE HCL EPHEDRINE SULPHATE ISOPRENALINE HCL METARAMINOL HA Standard Drugs Non-HA Standard Drugs General Drugs Special Drugs With Safety Net Without Safety Net MIDODRINE HCL NOREPINEPHRINE PHENYLEPHRINE HCL 2.8 Anticoagulants and protamine DALTEPARIN SODIUM ENOXAPARIN SODIUM NADROPARIN TINZAPARIN SODIUM HEPARIN PROTAMINE SULPHATE WARFARIN SODIUM ANTITHROMBIN III 2.9 Antiplatelet drugs ASPIRIN CLOPIDOGREL TICLOPIDINE HCL ASPIRIN + GLYCINE ABCIXIMAB DIPYRIDAMOLE EPTIFIBATIDE 2.10 Myocardial infarction and fibrinolysis STREPTOKINASE ALTEPLASE UROKINASE TENECTEPLASE 2.11 Antifibrinolytic drugs and haemostatics APROTININ FACTOR VIIA FACTOR IX FACTOR VIII FACTOR VIII INHIBITOR BYPASSING FRACTION FERRIC SUBSULPHATE FIBRINOGEN HUMAN TRANEXAMIC ACID 2.12 Lipid-regulating drugs ACIPIMOX ALPHA TOCOPHEROL NICOTINATE CHOLESTYRAMINE BEZAFIBRATE FENOFIBRATE EZETIMIBE GEMFIBROZIL MAXEPA (OR EQUIV) ATORVASTATIN NICOTINIC ACID FLUVASTATIN LOVASTATIN ROSUVASTATIN PRAVASTATIN SODIUM SIMVASTATIN 2.A Miscellaneous (Cardiovascular system) ADENOSINE TRIPHOSPHATE DISODIUM TRIMETAZIDINE HCL CARDIOPLEGIA (OR EQUIV) DAFLON 500 (OR EQUIV) SOLCOSERYL (OR EQUIV) UBIDECARENONE 3 Respiratory system 3.1 Bronchodilators AMINOPHYLLINE SALBUTAMOL PROCATEROL HCL HEMIHYDRATE THEOPHYLLINE TERBUTALINE SULPHATE SALBUTAMOL FORMOTEROL TERBUTALINE SULPHATE SALMETEROL (XINAFOATE) IPRATROPIUM BROMIDE TIOTROPIUM (BROMIDE) COMBIVENT (OR EQUIV) 3.2 Corticosteroids BECLOMETHASONE DIPROPIONATE BECLOMETHASONE DIPROPIONATE BUDESONIDE BUDESONIDE FLUTICASONE PROPIONATE BUDESONIDE + FORMOTEROL FLUTICASONE + SALMETEROL 3.3 Cromoglycate, related therapy and leukotriene receptor antagonists KETOTIFEN MONTELUKAST (SODIUM) CROMOGLYCATE SODIUM HA Standard Drugs Non-HA Standard Drugs General Drugs Special Drugs With Safety Net Without Safety Net 3.4 Antihistamines, hyposensitisation, and allergic emergencies ADRENALINE CETIRIZINE HCL ACRIVASTINE CHLORPHENIRAMINE MALEATE EBASTINE AZATADINE MALEATE CYPROHEPTADINE HCL FEXOFENADINE HCL DEXCHLORPHENIRAMINE MALEATE LORATADINE DIPHENHYDRAMINE HCL TELFAST D (OR EQUIV) HYDROXYZINE (HCL) CIRRUS PROMETHAZINE CLARINASE 3.5 Respiratory stimulants and pulmonary surfactants COLFOSCERIL PALMITATE INTRATRACHEAL DOXAPRAM HCL SURVANTA (BERACTANT) INTRATRACHEAL 3.6 Oxygen OXYGEN 3.7 Mycolytics ACETYLCYSTEINE ACETYLCYSTEINE (LOZENGES) AMBROXOL BROMHEXINE HCL CYCLIDROL MESNA (NEB SOLUTION) 3.9 Cough preparations ACTIFED (OR EQUIV) ACTIFED COMPOUND (OR EQUIV) AMMONIA IPECACUANHA COCILLANA (OR EQUIV) CODEINE PHOSPHATE COLD PREPARATION (OR EQUIV) DIMETAPP (OR EQUIV) DIPHENHYDRAMINE COMPOUND DRIXORAL S.R. (OR EQUIV) EXPECTORANT STIMULANT EXPECTORANT STIMULANT PRO INFANT FEDAC (OR EQUIV) GUAIPHENESIN IPECACUANHA NEOZEP (OR EQUIV) OPIATE SQUILL (GEES) PHOLCODINE PROMETHAZINE COMPOUND TIXYLIX (OR EQUIV) 3.10 Systemic nasal decongestants PSEUDOEPHEDRINE HCL 3.A Miscellaneous (Respiratory system) CAFFEINE FENSPIRIDE LYSOZYME CHLORIDE 4 Central nervous system 4.1 Hypnotics and anxiolytics CHLORAL HYDRATE FLUNITRAZEPAM FLURAZEPAM LORMETAZEPAM MIDAZOLAM NITRAZEPAM TRIAZOLAM ZOLPIDEM TARTRATE ZOPICLONE ALPRAZOLAM BROMAZEPAM BUSPIRONE HCL CHLORDIAZEPOXIDE DIAZEPAM HA Standard Drugs Non-HA Standard Drugs General Drugs Special Drugs With Safety Net Without Safety Net DIPOTASSIUM CLORAZEPATE LORAZEPAM PENTOBARBITAL SODIUM 4.2 Drugs used in psychoses and related disorders CHLORPROMAZINE HCL AMISULPRIDE DEHYDROBENZPERIDOL CLOZAPINE FLUPENTHIXOL OLANZAPINE FLUPHENAZINE QUETIAPINE (FUMARATE) HALOPERIDOL RISPERIDONE PERICYAZINE ZIPRASIDONE PERPHENAZINE PIMOZIDE SULPIRIDE THIORIDAZINE HCL THIOTHIXENE (HCL) TRIFLUOPERAZINE (HCL) ZUCLOPENTHIXOL LITHIUM CARBONATE 4.3 Antidepressant drugs AMITRIPTYLINE HCL CITALOPRAM (HBR) CLOMIPRAMINE HCL ESCITALOPRAM (OXALATE) DEANXIT (OR EQUIV) FLUVOXAMINE (MALEATE) DOTHIEPIN HCL PAROXETINE (HCL) DOXEPIN (HCL) SERTRALINE (HCL) IMIPRAMINE HCL MIRTAZAPINE MAPROTILINE HCL VENLAFAXINE (HCL) MIANSERIN HCL NORTRIPTYLINE (HCL) TRAZODONE HCL TRIMIPRAMINE MALEATE MOCLOBEMIDE FLUPENTHIXOL FLUOXETINE (HCL) 4.4 Central nervous system stimulants CAFFEINE METHYLPHENIDATE HCL 4.5 Drugs used in the treatment of obesity ORLISTAT 4.6 Drugs used in nausea and vertigo BETAHISTINE MESYLATE GRANISETRON (HCL) CINNARIZINE ONDANSETRON (HCL DIHYDRATE) CYCLIZINE HCL TROPISETRON (HCL) DIMENHYDRINATE DIMENHYDRINATE (SUPP) DOMPERIDONE FLUNARIZINE HYOSCINE MECLIZINE (HCL) METOCLOPRAMIDE HCL PROCHLORPERAZINE PROMETHAZINE 4.7 Analgesics ASPIRIN FENTANYL EPIZON RECTOCAP (OR EQUIV) (SUPP) MORPHINE SR NORGESIC (OR EQUIV) SUMATRIPTAN SUCCINATE PARACETAMOL ZOLMITRIPTAN PARACETAMOL (SUPP) BUPRENORPHINE (HCL) CODEINE PHOSPHATE DEXTROPROPOXYPHENE DIHYDROCODEINE DOLOGESIC (OR EQUIV) DOLOXENE CO (OR EQUIV) METHADONE MORPHINE HA Standard Drugs Non-HA Standard Drugs General Drugs Special Drugs With Safety Net Without Safety Net PENTAZOCINE HCL PETHIDINE HCL TRAMADOL
Load more

Recommended publications
  • United States Patent Office
    3,092,548 United States Patent Office Patented June 4, 1963 2 are the various side effects that occur in an appreciable 3,092,548 number of patients, the foremost of which are a blurring METHOD OF TREATING PEPTICULCERS WITH PANTOTHENECACD of vision, drowsiness and a general dry condition mani Albert G. Worton, Columbus, Ohio, assignor to The fested by a retarded salivation, reduction of perspiration Warren-Teed Products Company, Columbus, Ohio, a 5 and diminished urinary output. Other side effects which corporation of Ohio occur in some cases are glaucoma, stimulation of the cen No Drawing. Filed Oct. 27, 1960, Ser. No. 65,256 trol nervous system and in severe cases cardiac and respi 5 Claims. (Ci. 67-55) ratory collapse. These side effects increase to Some de gree with the increase in dosage. Despite the side effects This invention relates to preparation adapted for use O these compounds are fairly selective and highly effective in treating disorders of the gastro-intestinal tract, more in decreasing the volume and acidity of gastric secretion particularly in treating peptic ulcer, both of the duodenal and in reducing gastrointestinal motility. and gastric type, for hyperacidity, hypertropic gastritis, Understandably, the main problem in the past has been splenic flexure syndrome, biliary dyskinesia (postchole to provide a dosage of anticholinergic drug which will cystectomy syndrome) and hiatal hernia or other condi achieve the most beneficial results possible and yet mini tions where anticholinergic effect, either spasmolytic or mize the undesired side effects. One of the objects of antisecretory is indicated or where antiuicerogenic effect this invention is to provide novel compositions containing is indicated.
    [Show full text]
  • Isopropamide Iodide
    www.chemicalland21.com ISOPROPAMIDE IODIDE SYNONYMS (3-Carbamoyl-3,3-diphenylpropyl)diisopropylmethylammonium iodide; 2,2-Diphenyl-4- diisopropylaminobutyramide methiodide; 4-(Diisopropylamino)-2,2-diphenylbutyramide methiodide; gamma-(Aminocarbonyl)-N-methyl-N,N-bis(1-methylethyl)-gamma-phenylbenzenepropanaminium iodide; Iodure d'isopropamide; Ioduro de isopropamida; Isopropamide ioduro; Isopropamidi iodidum; Isoproponum iodide; PRODUCT IDENTIFICATION CAS RN 71-81-8 EINECS RN 200-766-8 FORMULA C23H33IN2O MOL WEIGHT 480.43 PHYSICAL AND CHEMICAL PROPERTIES PHYSICAL STATE white to off-white powder MELTING POINT 199 C BOILING POINT DENSITY SOLUBILITY IN WATER pH VAPOR DENSITY REFRACTIVE INDEX FLASH POINT GENERAL DESCRIPTION Isopropamide is a long-acting anticholinergic and antimuscarinic drug of quaternary ammonium structure. It is used in the form of the iodide, (also bromide or chloride) to treat peptic ulcer and to suppress gastric secretion other gastrointestinal disorders. Brands of Isopropamide drugs: Darbid Dipramide Isamide Marygin-M Piaccamide Priamide Priazimide Sanulcin Tyrimide Quaternary ammonium anticholinergics (Synthetic) ATC Code Product CAS RN. A03AB01 Benzilonium bromide 1050-48-2 A03AB02 Glycopyrrolate 596-51-0 A03AB03 Oxyphenonium 14214-84-7 A03AB04 Penthienate 22064-27-3 A03AB05 Propantheline 50-34-0 A03AB06 Otilonium bromide 26095-59-0 A03AB07 Methantheline 5818-17-7 Please mail us if you want to sell your product or need to buy some products) www.chemicalland21.com ISOPROPAMIDE IODIDE A03AB08 Tridihexethyl 60-49-1 A03AB09 Isopropamide 7492-32-2 A03AB10 Hexocyclium 6004-98-4 A03AB11 Poldine 596-50-9 A03AB12 Mepenzolic acid 25990-43-6 A03AB13 Bevonium 33371-53-8 A03AB14 Pipenzolate 13473-38-6 A03AB15 Diphemanil methylsulfate 62-97-5 A03AB16 (2-Benzhydryloxyethyl)diethyl-methylammonium iodide A03AB17 Tiemonium iodide 144-12-7 A03AB18 Prifinium bromide 4630-95-9 A03AB19 Timepidium bromide 35035-05-3 A03AB21 Fenpiverinium bromide 125-60-0 03AB53 Oxyphenonium, combinations STABILITY AND REACTIVITY STABILITY Stable under normal conditions.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al.
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • The Role of Antispasmodics in Managing Irritable Bowel Syndrome
    DOI: https://doi.org/10.22516/25007440.309 Review articles The role of antispasmodics in managing irritable bowel syndrome Valeria Atenea Costa Barney,1* Alan Felipe Ovalle Hernández.1 1 Internal Medicine and Gastroenterology specialist Abstract in San Ignacio University Hospital, Pontificia Universidad Javeriana, Bogotá, Colombia. Although antispasmodics are the cornerstone of treating irritable bowel syndrome, there are a number of an- tispasmodic medications currently available in Colombia. Since they are frequently used to treat this disease, *Correspondence: [email protected] we consider an evaluation of them to be important. ......................................... Received: 26/10/18 Keywords Accepted: 11/02/19 Antispasmodic, irritable bowel syndrome, pinaverium bromide, otilonium bromide, Mebeverin, trimebutine. INTRODUCTION consistency. The criteria must be met for three consecutive months prior to diagnosis and symptoms must have started Irritable bowel syndrome (IBS) is one of the most fre- a minimum of six months before diagnosis. (3, 4) quent chronic gastrointestinal functional disorders. It is There are no known structural or anatomical explanations characterized by recurrent abdominal pain associated with of the pathophysiology of IBS and its exact cause remains changes in the rhythm of bowel movements with either or unknown. Nevertheless, several mechanisms have been both constipation and diarrhea. Swelling and bloating are proposed. Altered gastrointestinal motility may contribute frequent occurrences. (1) to changes in bowel habits reported by some patients, and a IBS is divided into two subtypes: predominance of cons- combination of smooth muscle spasms, visceral hypersen- tipation (20-30% of patients) and predominance of dia- sitivity and abnormalities of central pain processing may rrhea (20-30% of patients).
    [Show full text]
  • Effect of Diazepam and Hyoscine Butylbromide on Response to Secretin and Cholecystokinin-Pancreozymin in Man
    Gut: first published as 10.1136/gut.17.5.351 on 1 May 1976. Downloaded from Gut, 1976, 17, 351-353 Effect of diazepam and hyoscine butylbromide on response to secretin and cholecystokinin-pancreozymin in man J. H. B. SAUNDERS, GUYA MASOERO, AND K. G. WORMSLEY' From the Department of Therapeutics, University of Dundee, Dundee SUMMARY Ten subjects received secretin and cholecystokinin or, in duplicate tests, the two hor- mones together with either diazepam or diazepam plus hyoscine butylbromide in order to determine whether these drugs, which are often used during retrograde endoscopic cannulation ofthe pancreatic duct, affect pancreatic and biliary secretion in response to the hormones. Diazepam with hyoscine butylbromide reduced the secretion of trypsin into the duodenum and delayed the appearance of both trypsin and bilirubin in duodenal aspirate. These effects must be taken into account when interpreting pancreatic and biliary responses measured during direct cannulation of the pancreatic duct. Endoscopic retrograde cannulation of the pancreatic vents in the antrum. Secretin (1 clinical unit/kg-h) duct has recently been used to measure pancreatic and cholecystokinin-pancreozymin (1 Ivy unit/ function by collecting the pancreatic juice directly kg-h) were administered for 45 minutes by continuous from the pancreatic duct during stimulation with intravenous infusion in 0 15 mol/1 sodium chloride. hormones et The exogenous (Cotton al., 1974; Gregg hormones had been purchased from the GIH http://gut.bmj.com/ et al., 1975; Robberecht et
    [Show full text]
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]